Fly News Breaks for March 5, 2015
BMY
Mar 5, 2015 | 09:03 EDT
After the FDA approved Bristol-Myers ' Opdivo to treat patients with advanced squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy, SunTrust indicates that the FDA approved the drug for use in more patients than expected. The firm says that the drug is poised to have dominant market share positions across lung, melanoma & renal cancers. SunTrust keeps a Buy rating on the shares.
News For BMY From the Last 2 Days
BMY
Apr 22, 2024 | 07:02 EDT
Bristol Myers Squibb and Cellares, a development and manufacturing organization dedicated to clinical and industrial-scale cell therapy manufacturing, announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380M in upfront and milestone payments. As part of the agreement, Cellares will optimize, automate, and tech-transfer select Bristol Myers Squibb CAR T cell therapies onto its automated and high-throughput manufacturing platform, the Cell Shuttle. Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb's exclusive use. The Cell Shuttles and Cell Qs will be deployed in Cellares' Smart Factories in the U.S., EU, and Japan. This agreement expands upon the existing collaborations between Bristol Myers Squibb and Cellares. In August 2023, Bristol Myers Squibb participated in Cellares' Series C financing to launch the first IDMO Smart Factory in an effort to meet the demand for cell therapies globally. That same month, Bristol Myers Squibb joined Cellares' Technology Adoption Partnership Program to evaluate the Cell Shuttle's automated manufacturing capabilities.